Cash Flow

v3.24.0.1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)
6 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Cash flows from operating activities    
Net (loss) income from operations $ (3,794,307) $ 72,164
Adjustments to reconcile net income from continuing operations to net cash provided by operating activities:    
Depreciation and amortization 2,958,553 2,268,120
Amortization of loan costs 30,274  
Amortization of senior security original issue discount   (192,690)
Amortization of consideration discount 734,824  
Non-cash consideration for sale of Infusionz and select assets, net 0 (7,094,296)
Inventory write-offs 90,030 34,328
Bad debt expense 0 0
Change in deferred tax asset (1,167,174) (15,089)
Noncontrolling interest 0 (233,586)
Shares issued for finder fee 0 1,770
Stock based compensation 752,471 1,980,173
Changes in assets and liabilities, net of acquired amounts    
Accounts receivable 1,943,520 1,274,387
Inventory (2,105,982) 3,748,625
Prepaid expenses and other assets 714,038 (983,244)
Operating lease payable (71,895) (24,573)
Accounts payable and accrued liabilities (2,174,628) 3,015,017
Deferred revenue (29,801) 0
Net cash provided by operating activities - Continuing Operations (2,120,077) 3,851,106
Net cash provided by (used in) operating activities - Discontinued Operations (223,957) (258,448)
Net cash provided by operating activities (2,344,034) 3,592,658
Cash flows from investing activities    
Acquisition of Lucky Tail 0 (2,500,000)
Acquisition of VitaMedica, Inc., net of cash acquired 0 (500,000)
Acquisition of New England Technology, Inc. 0 914,611
Acquisition of Interactive Offers, net of cash acquired 0 0
Proceeds from the sale of Interactive Offers, net of liabilities paid 147,592 0
Acquisition of patent rights for Tytan Tiles (70,000) 0
Acquisition of Cygnet Online LLC, net of cash acquired (500,000) 0
Proceeds from the sale of Infusionz and selected assets 0 5,500,000
Acquisition of property and equipment (480,456) (183,969)
Net cash provided by (used in) investing activities - Continuing Operations (902,864) 3,230,642
Net cash (used in) provided by investing activities - Discontinued Operations 0 0
Net cash provided by (used in) investing activities (902,864) 3,230,642
Cash flows from financing activities    
Repayment of notes payable (371,687) (350,877)
Repayment of the senior convertible notes payable 0 (6,382,989)
Proceeds (payments) on line of credit, net 3,284,532 (7,201,079)
Payment on acquisition notes payable (2,313,818)  
Proceeds from note payable 0 0
Proceeds on note payable on building 0 3,000,000
Proceeds on note payable, related party 0 1,470,000
Net cash used in financing activities - Continuing Operations 599,027 (9,464,945)
Net cash (used in) provided by financing activities - Discontinued Operations 0 0
Net cash used in financing activities 599,027 (9,464,945)
Net decrease in cash - Continuing Operations (2,423,914) (2,383,197)
Net (decrease) increase in cash - Discontinued Operations (223,957) (258,448)
Cash, beginning of period 4,492,291 7,149,806
Cash, end of period 1,844,420 4,508,161
Supplemental cash flow disclosures    
Interest paid 0 0
Income tax paid 0 0
Issuance of common stock for acquisition of Cygnet 162,727 0
Issuance of debt for acquisition of Cygnet 300,000 0
Bloomios non-cash payment of receivables, net 845,443 0
Liabilities assumed from acquisition of E-Core 0 (7,712,168)
Issuance of stock for acquisition of E-Core 0 6,000,000
Assets available for sale $ 0 $ 6,446,210

Source